7Baggers
The information provided in this report is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.

BioLineRx Ltd
(NASDAQ:BLRX) 

BLRX stock logo

BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. Its development pipeline consists of clinical-stage therapeutic candidates, which include BL-8040, a peptide for the treatment of solid tumors, hematological malignancies, and stem cell mobilization; AGI-134...

Founded: 2003
Full Time Employees: 42
Sector: Healthcare
Industry: Biotechnology

Share this website to your friends
BioLineRx Days Payable Outstanding ttm (DPO)
202303 202304 202305 202306 202307 202308 202309 202310 202311 202312 202401 202402 202403 202404 0508.651,017.31,525.952,034.62,543.253,051.893,560.54
BioLineRx Days Receivable Outstanding ttm (DSO)
202303 202304 202305 202306 202307 202308 202309 202310 202311 202312 202401 202402 202403 202404 07.6915.3823.0730.7638.4646.1553.84
BioLineRx Days Inventory Outstanding ttm (DIO)
202303 202304 202305 202306 202307 202308 202309 202310 202311 202312 202401 202402 202403 202404 081.5163244.5326407.5489570.5
BioLineRx Op Cashflow Per Share ttm
202209 202210 202211 202212 202301 202302 202303 202304 202305 202306 202307 202308 202309 202310 202311 202312 202401 202402 202403 202404 -0.54-0.46-0.38-0.31-0.23-0.15-0.080
BioLineRx Free Cashflow Per Share ttm
202209 202210 202211 202212 202301 202302 202303 202304 202305 202306 202307 202308 202309 202310 202311 202312 202401 202402 202403 202404 -0.55-0.47-0.39-0.31-0.23-0.16-0.080
BioLineRx Cash Per Share ttm
202209 202210 202211 202212 202301 202302 202303 202304 202305 202306 202307 202308 202309 202310 202311 202312 202401 202402 202403 202404 00.170.350.520.690.861.041.21
BioLineRx P/S ratio ttm
202303 202304 202305 202306 202307 202308 202309 202310 202311 202312 202401 202402 202403 202404 02.054.16.158.210.2412.2914.34
BioLineRx (GAAP) P/E ratio ttm
202209 202210 202211 202212 202301 202302 202303 202304 202305 202306 202307 202308 202309 202310 202311 202312 202401 202402 202403 202404 -8.3-7.12-5.93-4.74-3.56-2.37-1.190
BioLineRx P/B ratio ttm
202209 202210 202211 202212 202301 202302 202303 202304 202305 202306 202307 202308 202309 202310 202311 202312 202401 202402 202403 202404 01.022.053.074.15.126.147.17
No extra charts and metrics for this ticker.